Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Open Access

Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Gerardo Rodríguez‐LobatoOCOriol CardúsJMJoan Mañé-Pujol

Discussion

Loading...

Member takes

Overview

Observational analysis shows CAR T cells effectively control myeloma in cell lines, indicating dual targeting may enhance treatment.

Key Points

  • CAR T cells demonstrated cytolytic activity in controlling myeloma even with limited BCMA expression, highlighting therapeutic potential.
  • The analysis revealed effective targeting of CD229 antigen by CAR T cell therapy, showing promise in multiple myeloma treatment.
  • Co-culture experiments with K562 cell lines over 24 hours confirmed the specific activity of CAR T cells against CD229, supporting further research.
  • This research suggests dual targeting of BCMA and CD229 may improve outcomes in myeloma, calling for further clinical validation.

Cite This Study

Rodríguez‐Lobato et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fb76https://doi.org/10.1158/2326-6066.30029629
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  2. 2Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  3. 3Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  4. 4Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  5. 5Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025